PB1287 - Efficacy of Florio Haemo in improving health-related quality of life and treatment adherence in patients with Hemophilia

Background: Telehealth has revolutionized personalized care in hemophilia patients. Florio Haemo (FH) is divided into a platform for patients use on their smartphones and a dashboard for healthcare professionals. Patients can track and self-monitor their hemophilia-related events, including estimated plasma factor levels. Physicians can monitor patient clinical data in order to personalize therapy. Studies on the potential impact of FH on quality of life (QOL) in hemophilia patients are lacking.

Aims: To evaluate changes in QOL and treatment adherence in hemophilia patients after using FH.

Methods: We have conducted a quasi-experiment among hemophilia patients since February 2022. Enrolled individuals are severe hemophilia A or B patients on extended half-life recombinant factor 8 or 9 for prophylaxis without detectable inhibitors. Participants completed in person the assessment of five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) through EQ-5D survey before and after using FH. Statistical analysis was described using a t-test and SPSS software. The primary outcome was the change in the EQ-5D score, while the secondary outcome was treatment adherence.

Results: Preliminary data analysis revealed 12 enrolled patients from three Saudi centers. Table 1 summarizes demographic features. The mean age was 7 years, with a mean duration between the baseline and follow-up EQ-5D surveys of 5 months. 8 (67%) patients reported improvement in treatment adherence after using the platform. The use of FH was associated with a higher score of EQ-5D. The mean score of EQ-5D for participants increased after using FH from 76.7 (SD=18.5) to 85.8 (SD=15.8). Compared to their baseline, hemophilia patients using FH scored a statistically significant increase in QOL with a p-value of 0.01, 95%. [25.6, 2.7] Table 2.

Conclusion(s): Preliminary data revealed that FH use in hemophilia patients was associated with improvement in QOL. A larger cohort is required to confirm the consistency of these findings.